Zacks Research Has Strong Forecast for HALO FY2025 Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Equities researchers at Zacks Research lifted their FY2025 EPS estimates for Halozyme Therapeutics in a note issued to investors on Tuesday, December 10th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will post earnings per share of $4.45 for the year, up from their previous forecast of $4.40. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.80 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q3 2026 earnings at $1.44 EPS and FY2026 earnings at $5.84 EPS.

Other equities analysts also recently issued research reports about the company. Wells Fargo & Company downgraded Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and raised their target price for the company from $58.00 to $62.00 in a research report on Monday, October 7th. JMP Securities raised their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a report on Friday, November 1st. Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. HC Wainwright reiterated a “buy” rating and issued a $68.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday, November 20th. Finally, JPMorgan Chase & Co. lowered shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and boosted their price target for the stock from $52.00 to $57.00 in a research report on Thursday, September 19th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $61.11.

Halozyme Therapeutics Stock Up 0.4 %

HALO opened at $48.00 on Friday. The company has a market cap of $6.11 billion, a PE ratio of 15.89, a price-to-earnings-growth ratio of 0.43 and a beta of 1.23. Halozyme Therapeutics has a twelve month low of $33.15 and a twelve month high of $65.53. The company has a 50-day moving average price of $51.43 and a 200 day moving average price of $53.92. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of hedge funds have recently modified their holdings of the business. Geode Capital Management LLC lifted its position in Halozyme Therapeutics by 1.0% in the third quarter. Geode Capital Management LLC now owns 3,060,131 shares of the biopharmaceutical company’s stock valued at $175,194,000 after buying an additional 30,901 shares during the last quarter. Congress Asset Management Co. lifted its holdings in shares of Halozyme Therapeutics by 446.5% in the 3rd quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock worth $139,298,000 after acquiring an additional 1,988,238 shares during the last quarter. Handelsbanken Fonder AB boosted its position in shares of Halozyme Therapeutics by 76.9% during the 3rd quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock worth $112,715,000 after purchasing an additional 856,200 shares during the period. Dimensional Fund Advisors LP increased its holdings in Halozyme Therapeutics by 12.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company’s stock valued at $99,363,000 after purchasing an additional 209,530 shares during the last quarter. Finally, American Century Companies Inc. increased its holdings in Halozyme Therapeutics by 9.7% in the 2nd quarter. American Century Companies Inc. now owns 821,266 shares of the biopharmaceutical company’s stock valued at $43,002,000 after purchasing an additional 72,544 shares during the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction on Wednesday, October 9th. The stock was sold at an average price of $52.58, for a total transaction of $525,800.00. Following the completion of the sale, the chief executive officer now owns 676,744 shares of the company’s stock, valued at $35,583,199.52. This trade represents a 1.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 40,000 shares of company stock valued at $2,242,100 over the last ninety days. Company insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.